# Research Progress of Antibody-conjugated Drugs in Non-small Cell Lung Cancer

## TL;DR

This paper reviews the progress of antibody-drug conjugates in treating non-small cell lung cancer, highlighting their advantages and clinical outcomes.

## Contribution

The paper provides an overview of recent clinical advancements and challenges in ADCs for NSCLC treatment.

## Key findings

- ADCs offer precise targeting and improved patient tolerance compared to traditional chemotherapy.
- Clinical trials like DESTINY-Lung01 and TROPION-PanTumor01 show promising results for ADCs in NSCLC.
- Despite benefits, ADCs face challenges such as acquired resistance and toxicity.

## Abstract

肺癌是全球发病率第一位、病死率第二位的恶性肿瘤。非小细胞肺癌（non-small cell lung cancer, NSCLC）是最主要的肺癌病理分型。目前晚期NSCLC的一线标准治疗方案为免疫治疗、靶向治疗，虽然延长了患者的生存期，但获得性耐药仍是不可避免的。抗体偶联药物（antibody-drug conjugates, ADCs）是一类经由连接子将细胞毒性载荷与特异性单克隆抗体偶联制成的新型抗肿瘤药物，与化疗药物相比，ADCs具有精准识别、局部释放、患者耐受性高等优点，近年在NSCLC治疗方面显示出良好的临床获益。本文针对ADCs的作用机制、在晚期NSCLC中的临床研究进展以及存在的问题和挑战等方面进行概述。

Research data of DESTINY-Lung01

Research data of DESTINY-Lung02

TROPION-PanTumor01 dose amplification cohort study data

Summary of clinical trials of ADC in the treatment of NSCLC